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Abstract
Background: Secondary hyperparathyroidism (sHPT) is common in patients with chronic renal
failure. Despite the initiation of new therapeutic agents, several patients will require
parathyroidectomy (PTX). Total PTX with autotransplantation of parathyroid tissue (TPTX+AT)
and subtotal parathyroidectomy (SPTX) are currently considered as standard surgical procedures
in the treatment of sHPT. Recurrencerates after TPTX+AT or SPTX are between 10% and 12%
(median follow up: 36 months).
Recent retrospective studies demonstrated a lower rate of recurrent sHPT of 0–4% after PTX
without autotransplantation and thymectomy (TPTX) with no higher morbidity when compared to
the standard procedures. The observed superiority of TPTX is flawed due to different definitions
of outcomes, varying follow up periods and different surgical treatment strategies (with and
without thymectomy).
Methods/Design: Patients with sHPT (intact parathyroid hormone > 10 times above the upper
limit of normal) on long term dialysis (>12 months) will be randomized either to TPTX or
TPTX+AT and followed for 36 months. Outcome parameters are recurrence rates of sHPT,
frequencies of reoperations due to refractory hypoparathyroidism or recurrent/persistent
hyperparathyroidism, postoperative morbidity and mortality and quality of life. 50 patients per
group will be randomized in order to obtain relevant frequencies of outcome parameters that will
form the basis for a large scale confirmatory multicentred randomized controlled trial.
Discussion: sHPT is a disease with a high incidence in patients with chronic renal failure. Even a
small difference in outcomes will be of clinical relevance. To assess sufficient data about the rate of
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standardized conditions is mandatory.
Due to the existing uncertainties the calculated number of patients necessary in each treatment
arm (n > 4000) makes it impossible to perform this study as a confirmatory trial. Therefore
estimates of different outcomes are performed using a pilot MRCT comparing 50 versus 50
randomized patients in order to establish a hypothesis that can be tested thereafter.
If TPTX proves to have a lower rate of recurrent sHPT, no relevant disadvantages and no higher
morbidity than TPTX+AT, current surgical practice may be changed.




Secondary hyperparathyroidism (sHPT) is common in
patients with chronic renal failure, affecting most of those
who are receiving hemodialysis [1,2]. Overall 60.992
patients were treated with continuous haemodialysis for
renal failure in Germany 2004. The annual increase of 3%
in patients requiring haemodialysis appears constant
within the last years [3].
Renal insufficiency leads to a reduced synthesis of 1,25-
dihydroxy-Vitamin D secretion and a decrease in phos-
phate excretion resulting in hypocalcemia and hyperphos-
patemia. Consecutively, parathyroid hormone secretion
and parathyroid cell hyperplasia increases. With time,
sHPT is characterized by persistently elevated levels of
intact parathyroid hormone (PTH) above the desired tar-
get range recommended by the Kidney Disease Outcomes
Quality Initiative (KDOQI [4]) and complicated by
important disturbances in mineral metabolism and skele-
tal resistance to the calcemic actions of parathyroid hor-
mone [5-7]. Renal osteopathy is the most widely
recognized consequence of sHPT.
However, several reports indicate, that alterations in cal-
cium and phosphorus metabolism, as a result of either
sHPT or the therapeutic measures used to manage it, con-
tribute to soft-tissue and vascular calcification, cardiovas-
cular disease, and the risk of death [8-12].
Episodes of hypercalcemia and hyperphosphatemia are
often aggravated by the use of calcium as a phosphate-
binding agent, particularly in combination with Vitamin
D sterols, which increase the absorption of calcium and
phosphorus [12-15]. Recently, several new agents includ-
ing calcimimetics [16,17], new phosphate binders [18]
and less calcemic vitamin D analogues [19-22], have been
added to the list of therapeutic modalities in the manage-
ment of sHPT.
Despite the advent of these new therapeutic agents,
patients with long-standing sHPT often require parathy-
roidectomy. The indication for surgery depends on clini-
cal symptoms of progressive renal osteopathy and
impaired calcemic response following PTH secretion in
the absence of Vitamin D deficiency: either if hypercal-
cemia develops (spontaneously or under treatment with
Vitamin D), if the new therapeutic modalities fail to con-
trol sHPT or if medical therapy has to be adjourned
because of adverse reactions. However, the rate of parath-
yroidectomies (PTX) did not change significantly between
1991 and 2001 despite the progression in medical therapy
with phosphate binders and Vitamin D analogues [23].
Overall PTX is required in about 20% of patients after 3–
10 years of dialysis and up to 40% after 20 years [24,25].
Current treatment options
Three different surgical procedures are reported in the lit-
erature following the first PTX for secondary HPT in 1960
[26]: subtotal PTX (removal of three and a half glands and
leaving half of a gland as a remnant in the neck [27,28],
total PTX with autotransplantation (TPTX+AT) of some of
the excised tissue into defined areas (forearm muscle,
anterior tibial muscle or subcutaneously [28-31], and
total parathyroidectomy without autotransplantation
(TPTX) [32,33]. Ogg [34] initially reported that TPTX pro-
vides a feasible therapeutic option in patients who are on
chronic dialysis therapy. However, TPTX was not intro-
duced into clinical practice because of the potential com-
plication of adynamic bone disease or severe ongoing
hypocalcemia. Therefore subtotal PTX or TPTX+AT, both
supplemented with thymectomy, are currently considered
as the standard procedures in the treatment of sHPT
[28,32,35,36].
However, both procedures leave a fragment of activated,
proliferated parathyroid tissue, though at different sites.
Since the pathophysiological condition of chronic renal
failure and maintenance dialysis continues, the growth
stimulus persists and may cause recurrent sHPT at the sitePage 2 of 11
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observed at different intervals after initial surgery, it is
quite clear that the incidence of recurrent disease increases
with time [37,38]. A wide range of recurrence rates has
been published for both procedures (range 5–80%). This
variation is dependent on the definition of recurrent sHPT
and variability in follow up periods given in different
series for both techniques [32]. Recurrence-rates after
TPTX+AT or subtotal PTX after a median follow up of 36
months are reported to be between 10% and 12% [31,39-
41]. All other clinically relevant outcome parameters
(mortality and morbidity) do not differ significantly
between TPTX+AT and subtotal PTX [28,40,42].
The site of recurrence in patients after TPTX+AT is located
in approximately 80% at the graft (Figure 1) and in 20%
in the neck [24,36,43-47].
Graft-dependent recurrent sHPT after TPTX+AT can easily
be cured by excision of the parathyroid autotransplant
under local anaesthesia. If an operation is necessary for
recurrent sHPT after subtotal PTX, reexploration of the
neck is mandatory in all patients including the necessity
of general anaesthesia and the increased risk of recurrent
laryngeal nerve palsy [48]. Therefore, in case of recurrent
disease, subtotal PTX as preceding procedure is clearly
inferior to TPTX+AT given equal effectiveness for the ini-
tial treatment of sHPT.
Total parathyroidectomy without autotransplantation
and without routinely performed thymectomy (TPTX)
may provide an alternative strategy to the currently per-
formed procedures mainly because of the reported lower
rate of recurrent sHPT of 0–4% during long-term follow
up [32,36]. Patients after TPTX did not develop hypopar-
athyroidism [32,36] and particularly adynamic bone dis-
ease as initially expected [32,36,49-52]. Moreover,
patients lacking a parathyroid remnant maintained on a
noncritical calcium/phosphate product during the ongo-
ing follow-up, compared to individuals with persisting
parathyroid secretion after PTX [38].
One explanation for the absence of serious adverse events
may be that thymectomy was not performed on a regular
basis. The inferior parathyroid glands and the thymus
derive together from the third pharyngeal pouch. Even in
case of resection of all four parathyroid glands (TPTX)
residual microscopic parathyroid tissue or supernumerary
glands may be located in the thymus preventing the
patients to develop hypoparathyroidism and its sequelae
[29,40,53-56].
Aim of the study
The objective of this trial is to compare the different out-
comes of two different surgical strategies (TPTX+AT+ ver-
sus TPTX) for secondary hyperparathyroidism over a
three-year follow-up period.
Reducing the risk for recurrent sHPT is an important factor
for the patients and the health care system, as surgery for
recurrent sHPT is associated with high costs for localiza-
tion, a lesser cure-rate and a higher morbidity when com-
pared to intial parathyroidectomy [57]. All attempt
should be done to reduce the risk of its development.
Further more, TPTX without parathyroid autotransplanta-
tion and without thymectomy is associated with a reduced
operating time when compared to TPTX+AT thus leading
to reduced costs when compared to TPTX+AT.
Need for this study
To date, no prospective, randomized study exists compar-
ing TPTX to the standard surgical procedures. The existing
evidence of the potential superiority of TPTX regarding the
recurrence rate is flawed due to mainly methodological
problems of studies with different definitions of out-
comes, varying follow up periods, different surgical treat-
ment strategies (with and without thymectomy) and their
retrospective design. Therefore bias and chance are not
sufficiently controlled and the results of the present stud-
ies have to be interpreted with caution.
The difference observed between the rates of recurrent
sHPT of TPTX+AT and TPTX seems to be of clinical rele-
vance. To assess the true rates of both methods, a multi-
centred, randomized controlled trial (MRCT) under
standardized conditions is mandatory to achieve high
internal as well as external validity.
Due to the existing uncertainties the calculated number of
patients necessary in each treatment arm (n > 4000)
This figure shows the enlargement of a parathyroid autograft in a patient with recurrent s condary hyperparathyroidism, demonstrated by a knob underneath t e scarFigure 1
This figure shows the enlargement of a parathyroid autograft 
in a patient with recurrent secondary hyperparathyroidism, 
demonstrated by a knob underneath the scar.Page 3 of 11
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tory trial.
Therefore estimates of different outcomes are performed
using a pilot MRCT comparing 50 versus 50 randomized
patients in order to establish a hypothesis that can be
tested thereafter. This seems to be feasible and ethical.
Methods/Design
Objectives of the study
The objective of this study is to compare different out-
comes of TPTX and TPTX+AT for sHPT over a three-year
follow-up period. The information gained will be used for
further clinical trials.
The primary objective of this trial is to assess a better esti-
mate of the rates of recurrence of both methods. This shall
establish a hypothesis that can be tested thereafter.
Secondary objectives are divided into those occurring
intraoperative, postoperative until discharge and after dis-
charge until 36 months postoperatively.
Intraoperative categories comprise the duration of the sur-
gical procedures, the expertise of the responsible surgeon,
and complications and findings during surgery.
Within the postoperative setting until discharge, the fre-
quency of persistent hyperparathyroidism, the morbidity
and the length of hospital stay are noted. During follow
up, the frequency of persistent or recurrent sHPT, the fre-
quency of subsequent parathyroid autotransplantation
due to refractory hypoparathyroidism, the frequency of
reexploration of the neck or the parathyroid autograft, the
frequency of irreversible paralysis of the recurrent laryn-
geal nerve, the change of symptoms related to sHPT as
well as the change in quality of life and finally the inci-
dence of death are recorded.
Trial population
Patients on long-term (>12 months) dialysis with sHPT
(PTH ≥ tenfold above normal value) either with hypercal-
cemia (developing spontaneously or under treatment
with Vitamin D) or with normocalcemia in coincidence
with renal osteopathy.
Eligibility
Detailed inclusion and exclusion criteria are specified in
table 1.
Patients are screened consecutively for eligibility in all
participating centres after approval of the study protocol
by the local ethics committee. A contract has been signed
by the Study Centre of the German Surgical Society in Hei-
delberg (SDGC) and the participating hospitals for correct
conduction of the trial according to Good Clinical Prac-
tice. All participating surgeons performing the interven-
tions have been instructed by detailed manuals.
Consent
Patients who are scheduled for parathyroidectomy
because of sHPT will have a pretreatment visit to give
informed consent. During this visit the patient will be
screened and informed about the TOPAR PILOT trial. In
this conversation with the patient the study procedures,
risks, benefits and data management will be clarified in
detail.
Procedures for minimizing bias and blinding
Several appropriate methods are used in order to mini-
mize random and systematic sources of bias.
In order to achieve equal groups of patients free from sys-
tematic selection bias, an internet-based computer rand-
omization is performed after informed consent at each
centre. The main responsibility for the randomization
process lies at the SDGC in Heidelberg.
The internet-based computer randomization is performed
using the Randomizer for Clinical Trials 1.6.0, developed
at the Institute for Medical Informatics, Statistics and Doc-
umentation at Medical University of Graz, Austria. The
randomization is stratified by centres and is done to gen-
erate equal treatment groups by minimizing selection
bias. Stratification for the participating clinical sites
Table 1: Subject Inclusion and Exclusion Criteria
Inclusion criteria Exclusion criteria
• Patients on long term dialysis 
treatment (>12 months) with 
sHPT
• Primary or Tertiary 
hyperparathyroidism 
(hyperparathyroidism after kidney 
transplantation)
• PTH ≥ tenfold above upper 
normal value
• Familial 
hyperparathyroidism(MEN I, MEN 
II, hereditary 
hyperparathyroidism)
• Age equal or greater 18 years • History of neck explorations for 
thyroid/parathyroid disorders
• Informed consent • Malignant disease of the thyroid 
glands
• Bleeding disorder/coagulopathy
• Severe psychiatric or neurologic 
disease
• Drug- and/or alcohol-abuse
• Participation in another 
intervention-trial with 
interference of intervention and 
outcome
• Inability to follow the 
instructions given by the 
investigator (e.g. insufficient 
command of language)Page 4 of 11
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formed in high volume centres (defined as more than 15
parathyroidectomies per year for sHPT) minimizing bias
due to learning effects. No additional surgical training has
to be done as the neck exploration is the same in TPTX+AT
as in the standard procedure and in TPTX.
In order to obtain blinding in this trial a shame procedure
would be mandatory in the TPTX group for fake
autotransplantation which is in this case unethical due to
the design of a non confirmatory study.
Interventions
Preoperative interventions
Patients eligible to participate will be asked to give
informed consent. Patients will be randomised into the
following treatment groups thereafter.
Consecutively, baseline data will be documented at
screening visit, including past medical history, current
specific medication and current symptoms of sHPT. A
quality of life questionnaire (SF-36) will be handed out
preoperatively.
Surgical interventions
The responsible surgeon will document any particularities
of the surgical intervention and the estimated number of
similar operations he/she has performed so far. A stand-
ardized surgical approach to the parathyroids will be per-
formed in both groups:
With the patients under endotracheal anesthesia and with
the neck hyperextended, a Kocher's incision is made, pref-
erably in a skin crease. The incision line should be drawn
preoperatively, two fingerbreadths above the suprasternal
notch when the neck of the patient is extended. The sub-
cutaneous layer and platysm muscle is cut with electric
cautery. The upper flap is raised to the upper border of the
thyroid cartilage. The lower flap is mobilized to the
suprasternal notch. A retractor system is used to local
standards. The cervical fascia is incised in the midline. The
sternothyroid and sternohyoid muscles are retracted or
divided. On both sides, thyroid lobes are rotated medi-
ally, and the middle thyroid veins are divided. The lobes
are retracted medially one after another and the inferior
thyroid arteries and recurrent laryngeal nerves are identi-
fied.
TPTX Group
After mobilization of the thyroid gland, the parathyroid
glands have to be identified within the cricothyroid space
or in the thyrothymic tongue. Resection of all four (or
more) parathyroid glands is performed, carefully avoiding
any damage to the parathyroid capsules. The surgeon
must change gloves to avoid seeding of parathyroid cells
after preserving a part of each gland for pathology.
Thymectomy on one side is only performed, if only one
gland is found in the respective side or if palpation reveals
a suspicious mass within the thymus.
TPTX+AT Group
Performance of TPTX, supplemented by bilateral routine
cervical thymectomy as complete as possible.
Autotransplantation (AT): a small incision is made over
the brachioradial muscle of the non-shunt-bearing fore-
arm (alternative: muscles of the lower limb). After cutting
approximately 50 mg of the most normal appearing, e.g.
smallest, preferably nonnodular parathyroid gland into
pieces of 1 mm3 in size, 20 of these pieces are placed in
single muscle pockets each of the brachioradial muscle
which are closed by clips thereafter.
Histology procedures and crypreservation of resected specimen (both 
groups)
A small part of each gland has to be sent to pathology for
frozen section in order to confirm organ diagnosis. The
remaining parathyroid tissue will be placed in cold sterile
saline solution for later cryopreservation. Cryopreserva-
tion is performed by placing cut pieces of the selected par-
athyroid gland into a vial containing a solution of 80%
culture media, 10% patient serum and 10% dimethyl sul-
foxide. The vial is then cooled to 70°C at a rate of 1°C per
minute.
Postoperative interventions
At day of discharge from hospital, the laboratory parame-
ters and current specific medication are documented
again. Patients are asked to fill out another quality of life
questionnaire (SF-36). Assessment of vocal cord function
has to be documented.
After discharge a follow up visits at 6, 12, 24 and 36
months postoperatively are performed. Follow-up visits
consist of a telephone call, a written questionnaire (med-
ical history, current specific medication and specific
symptoms and a quality of life questionnaire (SF-36)) to
the patient, who is asked to complete it with the help of
their general practitioner or nephrologists. The follow up
is under the responsibility of the centres under supervi-
sion of the SDGC.
Figure 2 shows a flow-chart of the interventions.
Number of patients needed
This trial is designed on the basis of a critical appraisal of
the existing evidence. The observed difference between
the recurrence rates of TPTX+AT and TPTX is of clinical rel-
evance. To assess both methods a multicentred rand-
omized controlled trial is mandatory.Page 5 of 11
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In the context of a noninferiority design with a binary pri-
mary endpoint using the confidence interval approach for
the odds ratio a sample size of 2 × 656 = 1310 patients
would be needed to detect non-inferiority with δ = 1588
based on equal risks of recurrence in both groups (or
lower in TPTX) with a power of 80% and a significance
level of 5% (Monte-Carlo simulation using logistic regres-
sion). Incorporating a rate of drop-outs of 15%, 2 × 770 =
1540 patients would be needed. In case of slight differ-
ences between the centres the power will not change sig-
nificantly. Assuming that a risk of 12,5% in the TPTX+AT
group is not inferior based on the risk rate of 10% in the
TPTX group (difference of 0.025 or an odds ratio of 1.286)
would lead to a sample size of more than 4000 and is
therefore far from feasibility. The latter margin is the same
as usually used for bioequivalence trials (change of 80%
or 125%). Therefore better estimates are needed and a
pilot multicentred randomized controlled trial comparing
50 versus 50 randomized patients seems feasible and eth-
ical to assess the recurrence rate of both methods after
three years in specialized centres.
Clinical sites
Sites are selected according to their experience in parathy-
roid surgery and willingness to adhere to the clinical trial
protocol. The surgical expertise of each participating sur-
geon is documented and taken into account during the
analysis of the trial data.
Safety aspects
A small part of each gland is sent to pathology for frozen
section in order to confirm organ diagnosis. The success of
the intervention is assessed by perioperative monitoring
of PTH and calcium recorded in the CRF. All participating
centres guarantee cryopreservation of parathyroid tissue
from each patient to enable possible subsequent parathy-
roid autotransplantation, if necessary. If postoperative
persistent hypoparathyroidism refractory to medical treat-
ment occurs, reimplantation is performed. The necessity
of reimplantation is discussed and defined in each indi-
vidual case by a medical clinical expert board. Therefore,
clinical symptoms (e.g. repeated episodes of paraesthesia
and seizures or others), the necessity and amount of med-
ication to achieve normocalcemia and laboratory data
(PTH, calcium) will be taken into consideration.
All serious adverse events (SAE) have to be reported to the
principal investigator and the leading ethic committee.
For the safety analysis the incidence of adverse events (AE)
and SAE are analyzed. Patients may be withdrawn from
the study at any time either at their own request or at the
request of the principal investigator.
Safety evaluation will be done. The adverse events of both
treatment groups will be demonstrated in comparison
considering severity and causality. Safety interim analyses
are planned each year and the independent data and
safety board will follow the progress of the trial to control
the safety.
Statistical Analysis
Statistical methods are used to assess the quality of data,
homogeneity of treatment groups, endpoints and safety of
the TPTX versus TPTX+AT technique. The analysis is per-
formed on the basis of an intention to treat (ITT) popula-
tion and with respect to ITT principles. A patient belongs
to the ITT population, when the patient was found to be
suitable for the study, signed the informed consent form
and was randomized thereafter.
Descriptive analysis
Baseline characteristics as well as efficacy and safety end-
points will be analyzed with descriptive methods. The
description of continuous variables includes at least:
This figure represents a flowchart comprising all the inter-ventions of the TOPAR PILOT trialFigure 2
This figure represents a flowchart comprising all the inter-
ventions of the TOPAR PILOT trial.
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median, minimum and maximum in the trial population.
The description of nominal variables includes at least the
number and percentage of patients belonging to the rele-
vant categories in the trial population as well as in each
treatment group. In order to improve the presentation of
the observed data, graphical methods will be applied.
Trial organization, quality control and registration
TOPAR PILOT was designed at the Department for Vis-
ceral, Thoracic and Vascular Surgery, Philipps-University,
Marburg in cooperation with the Study Centre of the Ger-
man Surgical Society (SDGC), Heidelberg and the Insti-
tute of Medical Biometrics and Informatics (IMBI) at the
University of Heidelberg.
Quality assurance will be done in cooperation with the
Network of Coordinating Centres for Clinical Trials
(KKS).
The trial is monitored by an independent monitor of the
KKS in Heidelberg. The trial is performed according to the
Declaration of Helsinki in its current German version and
the Good Clinical Practice (GCP). Before the start of the
trial the independent ethics committee of the Philipps-
University, Marburg gave a positive vote on August 21th
2006. The trial was registered on August 22d in 2006 at
the International Standard Randomized Controlled Trial
Number Registration (ISRCTN86202793).
Financial support
This trial is funded by the German Federal Ministry of
Education and Research [Bundesministerium für Bildung
und Forschung (BMBF); 01GH99033] and the German
Surgical Society [Deutsche Gesellschaft für Chirurgie
(DGCH)]. Additional industrial funding for the infra-
structure of the SDGC is received from Ethicon GmbH,
Norderstedt, Germany, and Tyco Healthcare Deutschland
GmbH, Neustadt, Germany.
Current status and duration of the trial
Up to now, 2 centres are initiated. The first patient was
randomized on January 24th 2007. The expected recruit-
ment period will last 18 months.
Discussion
TOPAR PILOT is a randomized controlled multicentred
pilot trial to generate high quality evidence comparing the
outcomes of TPTX+AT vs. TPTX. Since secondary hyper-
parathyroidism is a very common disease in patients with
chronic kidney failure, even a small difference in out-
comes will be of clinical relevance. If TPTX proves to have
no relevant disadvantages and a smaller rate of recurrent
sHPT, a large scale confirmatory study will be launched to
establish this approach.
Recent reports comparing TPTX+AT to TPTX were retro-
spective, underpowered or not designed as RCT's. No
unique definition for recurrent sHPT was used to calculate
the rate of recurrent sHPT. The follow up periods of
former studies have often been too short and were not
standardized (table 2). Therefore we will perform a follow
up of each patient at 6, 12, 24 and 36 months after surgery
to allow an assessment of the medium/long term effect of
the different surgical treatments.
The evaluation of optimal surgical options and proce-
dures should be performed according to the best current
knowledge. Due to the principles of Evidence-based Med-
icine (EbM), the randomized controlled trial is assumed
to be the "Gold Standard" in evaluating different medical
methods and procedures. Even in RCT's, the risk of bias
should not be underestimated. In surgical trials a double
blinded trial design is difficult to establish. In this study,
even a patient-blinded trial design would necessitate a
shame procedure at the forearm for fake autotransplanta-
tion in the TPTX-group which is in this case unethical due
to the design of a non confirmatory study.
However, the patient selection, power, randomization,
surgeon's skill, data assessment and documentation of
outcome measures and statistical analysis are important
design issues and susceptible to the different forms of
bias. Hence, all these issues are specified in the trial proto-
col a priori.
Selection bias
To minimize selection bias all patients scheduled for par-
athyroidectomy because of sHPT are screened consecu-
tively in all participation sites. Moreover, neither patient
age nor the amount of PTH-secretion is an exclusion crite-
rion. Screening lists and case report files are monitored by
independent investigators from the SDGC to ensure cor-
rect patient recruitment and meticulous documentation.
Randomization bias
Randomization is done using in an internet-based com-
puter randomization. The randomization will be stratified
by centres and will be done to generate equal treatment
groups by minimizing selection bias. Stratification for the
participating clinical sites will reduce bias due to centre
effects.
Surgeon's expertise bias
In this study, stratification for surgeon's skill is made and
measured data will be analyzed by analysis of variance in
regard to surgeon's skill and centre. Due to this analysis of
variance, bias of centre effects and surgeon's skill should
be reduced.Page 7 of 11
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(defined as more than 15 parathyroidectomies per year
for sHPT) minimizing bias due to learning effects. No
additional surgical training has to be done as the neck
exploration is the same in TPTX as in the standard proce-
dure of TPTX+AT.
In conclusion, this is the first randomized controlled mul-
ticentred trial comparing different surgical techniques in
parathyroid surgery for sHPT. If significant, the results will
be revised by a large scale confirmatory study. The results
may change the current surgical practice thereafter.
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Table 2: Rate of recurrent sHPT after TPTX or TPTX+AT
Reference TPTX+ AT n TPTX n Routinely performed 
thymectomy
Mean length of follow – 
up (months)
Recurrent sHPT1 (%)
Rothmund et al. 1991 
[29]
20 yes 43 0
Zaraca et al. 1999 [58] 18 no, only if palpation was 
suspicious or parathyroid 
gland was missing
28 10
Walgenbach et al. 
1997 [46]
67 yes 18 4.5
Walgenbach et al. 
1998 [59]
86 yes 24 3.5
Henry et al.1990 [40] 152 no 30 10.5
Welk and Alix 1987 
[60]
21 n.m. 33 24
Hampl et al. 1991 [37] 13 yes 33.5 76.5
Chou et al. 2002 [61] 75 n.m. 54 13.3
Bessell et al. 1993 84 42 n.m. 40 9.5
Dotzenrath et al. 2003 
[62]
99 yes 51 6
Korzets et al. 1987 
[63]
19 n.m. 6–60 26.3
Kinnaert et al. 2000 
[31]
59 no 38 12
Tominaga et al. 1997 
[39]
519 yes 36 10
60 20
Ockert et al. 2002 
[32]
11 no 38 45
11 no 22.5 0
Kaye et al. 1993 [64] 13 n.m. 46 0
Higgins et al. 1991 
[44]
34 no 72 80
9 no 10 0
Nicholson 1996 [36] 13 no 24 16
24 no 24 0
Saunders et al. 2005 
[52]
55 no 29 4
Stracke et al. 1999 
[35]
20 n.m. 20 4
Hampl et al. 1999 [65] 11 no 26 0
Ljutic D et al. 1994 
[66]
43 no 104 2.3
n.m. = not mentioned
1 Recurrent sHPT is defined as an increase of PTH > 5 fold above normal value after more than 6 months after initial PTX and after initial 
(postoperative) normalization of PTH.Page 8 of 11
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